U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H27NO3
Molecular Weight 305.4119
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of CAPSAICIN

SMILES

COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1

InChI

InChIKey=YKPUWZUDDOIDPM-SOFGYWHQSA-N
InChI=1S/C18H27NO3/c1-14(2)8-6-4-5-7-9-18(21)19-13-15-10-11-16(20)17(12-15)22-3/h6,8,10-12,14,20H,4-5,7,9,13H2,1-3H3,(H,19,21)/b8-6+

HIDE SMILES / InChI
Molecular Formula C18H27NO3
Molecular Weight 305.4119
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/mtm/capsaicin-topical.html http://www.rxlist.com/qutenza-drug.htm http://www.wikidoc.org/index.php/Capsaicin

Capsaicin is a topical analgesic that is FDA approved for the treatment of neuropathic pain associated with postherpetic neuralgia. Capsaicin is most often used as a topical analgesic and exists in many formulations of cream, liquid, and patch preparations of various strengths; however, it may also be found in some dietary supplements. Capsaicin is a naturally-occurring botanical irritant in chili peppers, synthetically derived for pharmaceutical formulations. Capsaicin is an agonist for the transient receptor potential vanilloid I receptor (TRPVI), which is an ion channel-receptor complex expressed on nociceptive nerve fibers in the skin. Common adverse reactions include erythema, rash, pruritus, nausea.

CNS Activity

Originator

Approval Year

1988
110
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2662
 1.8 µM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Approved
8360
QUTENZA

Approved Use

Qutenza is indicated for the management of neuropathic pain associated with postherpetic neuralgia

Launch Date

1.2583296E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.38 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/19494795/
640 μg/cm² single, topical
dose: 640 μg/cm²
route of administration: Topical
experiment type: SINGLE
co-administered:
CAPSAICIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4.36 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/19494795/
640 μg/cm² single, topical
dose: 640 μg/cm²
route of administration: Topical
experiment type: SINGLE
co-administered:
CAPSAICIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.64 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/19494795/
640 μg/cm² single, topical
dose: 640 μg/cm²
route of administration: Topical
experiment type: SINGLE
co-administered:
CAPSAICIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
8 % single, topical
Recommended
Dose: 8 %
Route: topical
Route: single
Dose: 8 %
Sources:
https://pubmed.ncbi.nlm.nih.gov/20655809
Page: p.975
unhealthy, 71.6 +/-10.27
n = 222
Health Status: unhealthy
Condition: Neuropathic pain associated with postherpetic neuralgia
Age Group: 71.6 +/-10.27
Sex: M+F
Population Size: 222
Sources:
https://pubmed.ncbi.nlm.nih.gov/20655809
Page: p.975
Disc. AE: Neuralgia...
AEs leading to
discontinuation/dose reduction:
Neuralgia (0.9%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/20655809
Page: p.975
8 % 1 times / 3 months multiple, topical
Recommended
Dose: 8 %, 1 times / 3 months
Route: topical
Route: multiple
Dose: 8 %, 1 times / 3 months
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022395lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Neuropathic pain associated with postherpetic neuralgia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022395lbl.pdf
Page: p.1
Other AEs: Irritation of eyes, Respiratory tract irritation...
Other AEs:
Irritation of eyes
Respiratory tract irritation
Transient blood pressure increase
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022395lbl.pdf
Page: p.1
AEs

AEs

AESignificanceDosePopulation
Neuralgia 0.9%
Disc. AE
8 % single, topical
Recommended
Dose: 8 %
Route: topical
Route: single
Dose: 8 %
Sources:
https://pubmed.ncbi.nlm.nih.gov/20655809
Page: p.975
unhealthy, 71.6 +/-10.27
n = 222
Health Status: unhealthy
Condition: Neuropathic pain associated with postherpetic neuralgia
Age Group: 71.6 +/-10.27
Sex: M+F
Population Size: 222
Sources:
https://pubmed.ncbi.nlm.nih.gov/20655809
Page: p.975
Irritation of eyes
8 % 1 times / 3 months multiple, topical
Recommended
Dose: 8 %, 1 times / 3 months
Route: topical
Route: multiple
Dose: 8 %, 1 times / 3 months
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022395lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Neuropathic pain associated with postherpetic neuralgia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022395lbl.pdf
Page: p.1
Respiratory tract irritation
8 % 1 times / 3 months multiple, topical
Recommended
Dose: 8 %, 1 times / 3 months
Route: topical
Route: multiple
Dose: 8 %, 1 times / 3 months
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022395lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Neuropathic pain associated with postherpetic neuralgia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022395lbl.pdf
Page: p.1
Transient blood pressure increase
8 % 1 times / 3 months multiple, topical
Recommended
Dose: 8 %, 1 times / 3 months
Route: topical
Route: multiple
Dose: 8 %, 1 times / 3 months
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022395lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Neuropathic pain associated with postherpetic neuralgia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022395lbl.pdf
Page: p.1
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1010

inhibitor
1752

inducer
383
inhibitor
1837

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
1509

CYP2B6
799

CYP2C19
1463

CYP2E1
876

CYP3A4/5
273
CYP2C19
985
CYP1A2
689

CYP2B6
538

CYP2C19
290

CYP2E1
126

CYP3A4/5
120
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
1673
 no
trans-capsaicin
2
CYP2B6
985
 no
trans-capsaicin
2
CYP2C19
1537
 no
trans-capsaicin
2
CYP2C9
1803
 no
trans-capsaicin
2
CYP2E1
964
 no
trans-capsaicin
2
CYP3A4/5
330
 no
trans-capsaicin
2
CYP3A4/5
330
 unlikely [IC50 12 uM]
trans-capsaicin
2
CYP2D6
1875
 unlikely [IC50 18 uM]
trans-capsaicin
2
CYP2C9
1803
 unlikely [IC50 2 uM]
trans-capsaicin
2
CYP1A2
1673
 unlikely [IC50 2.1 uM]
trans-capsaicin
2
CYP2B6
985
 unlikely [IC50 24 uM]
trans-capsaicin
2
CYP2C19
1537
 unlikely [IC50 3.2 uM]
trans-capsaicin
2
CYP2E1
964
 unlikely [IC50 >10 uM]
trans-capsaicin
2
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP2C9
1010
 major
CYP2C19
985
 yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:3374
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3374
ChemicalBook
CB32551563
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB32551563
ChemicalBook
CB6112967
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB6112967
MolPort
MolPort-001-742-263
https://www.molport.com/shop/molecule-link/MolPort-001-742-263
ZINC
ZINC000001530575
http://zinc15.docking.org/substances/ZINC000001530575
eMolecules
479469
https://www.emolecules.com/cgi-bin/more?vid=479469
PubMed

PubMed

TitleDatePubMed
Activation of peripheral kappa opioid receptors inhibits capsaicin-induced thermal nociception in rhesus monkeys.
1999 Apr
Brain processing of capsaicin-induced secondary hyperalgesia: a functional MRI study.
1999 Aug 11
Effect of sympathetic activity on capsaicin-evoked pain, hyperalgesia, and vasodilatation.
1999 Mar 23
Capsaicin-sensitive afferent sensory nerves in modulating gastric mucosal defense against noxious agents.
1999 Nov
Capsaicin inhibits phospholipase C-mediated Ca(2+) increase by blocking thapsigargin-sensitive store-operated Ca(2+) entry in PC12 cells.
1999 Oct
Protective effect of lafutidine against indomethacin-induced intestinal ulceration in rats: relation to capsaicin-sensitive sensory neurons.
2000
Alterations in spinal cord Fos protein expression induced by bladder stimulation following cystitis.
2000 Apr
Local inhibitory effects of dynorphin A-(1-17) on capsaicin-induced thermal allodynia in rhesus monkeys.
2000 Aug 18
Effect of ginsenosides, active components of ginseng, on capsaicin-induced pain-related behavior.
2000 Aug 23
Induction of vanilloid receptor channel activity by protein kinase C.
2000 Dec 21-28
Cholecystokinin-8 enhances nerve growth factor synthesis and promotes recovery of capsaicin-induced sensory deficit.
2000 Feb
Evidence for activation of the tissue kallikrein-kinin system in nociceptive transmission and inflammatory responses of mice using a specific enzyme inhibitor.
2000 Jul
Spatial mapping of the zone of secondary hyperalgesia reveals a gradual decline of pain with distance but sharp borders.
2000 May
Effect of oral mexiletine on capsaicin-induced allodynia and hyperalgesia: a double-blind, placebo-controlled, crossover study.
2000 Sep-Oct
Influence of capsaicin cream in rats with peripheral neuropathy.
2001 Aug
Comparative effect of Phoneutria nigriventer spider venom and capsaicin on the rat paw oedema.
2001 Aug 17
Improvement of preservation with cardioplegic solution by nitroglycerin-induced delayed preconditioning is mediated by calcitonin gene-related peptide.
2001 Dec
Effects of vanilloid receptor agonists and antagonists on gastric antral ulcers in rats.
2001 Dec 7
Chronic tobacco smoke exposure increases airway sensitivity to capsaicin in awake guinea pigs.
2001 Feb
Analysis of the native quaternary structure of vanilloid receptor 1.
2001 Jul 27
Antinociceptive effects of delta-opioid agonists in Rhesus monkeys: effects on chemically induced thermal hypersensitivity.
2001 Mar
Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues.
2001 May 25
Transient inhibition of the human motor cortex by capsaicin-induced pain. A study with transcranial magnetic stimulation.
2001 Nov 13
Nitric oxide synthase in spinal cord central sensitization following intradermal injection of capsaicin.
2001 Oct
Effect of systemic adenosine on pain and secondary hyperalgesia associated with the heat/capsaicin sensitization model in healthy volunteers.
2001 Sep-Oct
Intestinal protection by lafutidine, a histamine H(2)-receptor antagonist, against indomethacin-induced damage in rats--role of endogenous nitric oxide.
2001 Sep-Oct
Ischemia/reperfusion-induced increase in the hepatic level of prostacyclin is mainly mediated by activation of capsaicin-sensitive sensory neurons in rats.
2002 Apr
Delayed cardioprotection induced by nitroglycerin is mediated by alpha-calcitonin gene-related peptide.
2002 Apr
The addition of glyceryltrinitrate to capsaicin cream reduces the thermal allodynia associated with the application of capsaicin alone in humans.
2002 Apr 19
Pharmacological characterisation of the somatostatin analogue TT-232: effects on neurogenic and non-neurogenic inflammation and neuropathic hyperalgesia.
2002 Aug
Concentration-effect relationships for intravenous alfentanil and ketamine infusions in human volunteers: effects on acute thresholds and capsaicin-evoked hyperpathia.
2002 Jan
Preliminary efficacy assessment of intrathecal injection of an American formulation of adenosine in humans.
2002 Jan
Role of bradykinin in acid-induced mesenteric hyperemia and duodenal villous damage.
2002 Jan 4
5-Hydroxytryptamine(1B/1D) and 5-hydroxytryptamine1F receptors inhibit capsaicin-induced c-fos immunoreactivity within mouse trigeminal nucleus caudalis.
2002 Jun
Cell death of primary afferent nerve cells in neonatal mice treated with capsaicin.
2002 Mar
The orofacial capsaicin test in rats: effects of different capsaicin concentrations and morphine.
2002 Mar
HSP90 inhibitors alter capsaicin- and ATP-induced currents in rat dorsal root ganglion neurons.
2002 Mar 25
Pain activation of human supraspinal opioid pathways as demonstrated by [11C]-carfentanil and positron emission tomography (PET).
2002 Oct
Assessment of the reproducibility of intradermal administration of capsaicin as a model for inducing human pain.
2002 Sep
Naloxone increases pain induced by topical capsaicin in healthy human volunteers.
2002 Sep
Capsaicin-induced muscle pain alters the excitability of the human jaw-stretch reflex.
2002 Sep
Patents

Patents

JP2000014370A
2
JP2000014393A
2
JP2000026260A
13
JP2000086504A
2
JP2000106824A
2
JP2000143507A
2
JP2000159664A
2
JP2000178192A
2
JP2000189108A
2
JP2000204046A
2
JP2000212477A
2
JP2000247875A
2
JP2000249697A
3
JP2000281568A
2
JP2000297036A
2
JP2001019604A
2
JP2001035268A
2
JP2001046096A
3
JP2001064164A
2
JP2001078708A
2
JP2001136920A
2
JP2001157558A
2
JP2001172114A
2
JP2001245627A
2
JP2001258497A
2
JP2001258499A
2
JP2001261504A
2
JP2001278723A
2
JP2001288077A
2
JP2001322921A
2
JP2001506541A
7
JP2001523085A
3
JP2002186469A
2
JP2002218950A
2
JP2002226400A
2
JP2002522488A
2
JP2002536118A
41
JP2002537317A
95
JP2002537330A
2
JP2003047432A
2
JP2003143744A
2
JP2003210164A
2
JP2003500349A
3
JP2004043350A
2
JP2004075666A
2
JP2004081107A
2
JP2004081180A
2
JP2004115382A
2
JP2004175723A
6
JP2004217554A
2
JP2004283152A
2
JP2008525505A
3
JP2008539253A
2
JP4705912B2
45

Sample Use Guides

In Vivo Use Guide
The recommended dose of Qutenza is a single, 60-minute application of up to four patches. Qutenza patch contains 8% capsaicin (640 mcg/cm2).
Route of Administration: Topical
In Vitro Use Guide
In isolated perfused globally ischemic rat hearts, antiischemic efficacy was assessed as a significant extension (36% and 50%) in time to contracture with 30 microM capsaicin and 1 microM diltiazem, respectively.
Substance Class Chemical
Created
by admin
on Wed Jul 05 22:42:42 UTC 2023
Edited
by admin
on Wed Jul 05 22:42:42 UTC 2023
Record UNII
S07O44R1ZM
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CAPSAICIN
DASH   EMA EPAR   HSDB   INCI   INN   JAN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD  
INN   INCI  
Official Name English
CAPSAICIN [MART.]
Common Name English
CAPSAICIN [JAN]
Common Name English
OVOCAP
Common Name English
CNTX-4975
Common Name English
CAPSAICIN [EMA EPAR]
Common Name English
AUSANIL
Common Name English
TRANS-CAPSAICIN
Common Name English
(E)-8-Methyl-N-vanillyl-6-nonenamide
Systematic Name English
capsaicin [INN]
Common Name English
NGX-4010
Code English
RATDEN PE 40
Common Name English
NSC-56353
Code English
CAPSAICIN [ORANGE BOOK]
Common Name English
QUTENZA
Brand Name English
6-NONENAMIDE, (E)-N-((4-HYDROXY-3-METHOXY-PHENYL)METHYL)-8-METHYL
Common Name English
Capsaicin [WHO-DD]
Common Name English
ZOSTRIX
Common Name English
CAPSAICIN (CONSTITUENT OF CAPSICUM) [DSC]
Common Name English
CAPSAICIN [HSDB]
Common Name English
TOGARASHI ORENJI
Common Name English
FEMA NO. 3404
Code English
CAPSAICIN [USP MONOGRAPH]
Common Name English
CAPSAICIN [INCI]
Common Name English
N-(4-HYDROXY-3-METHOXYBENZYL)-8-METHYL-6-NONENAMIDE [FHFI]
Common Name English
ALGRX-4975
Code English
MIOTON
Common Name English
CAPSAICIN [USP-RS]
Common Name English
ALGRX 4975
Code English
CAPSAICIN [MI]
Common Name English
NGX-1998
Code English
CAPSAICIN [VANDF]
Common Name English
CAPZASIN-HP
Common Name English
DOLENON
Common Name English
AXSAIN
Common Name English
Classification Tree Code System Code
EPA PESTICIDE CODE 70701
Created by admin on Wed Jul 05 22:42:42 UTC 2023 , Edited by admin on Wed Jul 05 22:42:42 UTC 2023
FDA ORPHAN DRUG 269508
Created by admin on Wed Jul 05 22:42:42 UTC 2023 , Edited by admin on Wed Jul 05 22:42:42 UTC 2023
NCI_THESAURUS C68530
Created by admin on Wed Jul 05 22:42:42 UTC 2023 , Edited by admin on Wed Jul 05 22:42:42 UTC 2023
FDA ORPHAN DRUG 165502
Created by admin on Wed Jul 05 22:42:42 UTC 2023 , Edited by admin on Wed Jul 05 22:42:42 UTC 2023
WHO-VATC QM02AB01
Created by admin on Wed Jul 05 22:42:42 UTC 2023 , Edited by admin on Wed Jul 05 22:42:42 UTC 2023
EMA ASSESSMENT REPORTS QUTENZA (AUTHORIZED: NEURALGIA)
Created by admin on Wed Jul 05 22:42:42 UTC 2023 , Edited by admin on Wed Jul 05 22:42:42 UTC 2023
FDA ORPHAN DRUG 158202
Created by admin on Wed Jul 05 22:42:42 UTC 2023 , Edited by admin on Wed Jul 05 22:42:42 UTC 2023
WHO-ATC N01BX04
Created by admin on Wed Jul 05 22:42:42 UTC 2023 , Edited by admin on Wed Jul 05 22:42:42 UTC 2023
WHO-ATC M02AB01
Created by admin on Wed Jul 05 22:42:42 UTC 2023 , Edited by admin on Wed Jul 05 22:42:42 UTC 2023
FDA ORPHAN DRUG 222506
Created by admin on Wed Jul 05 22:42:42 UTC 2023 , Edited by admin on Wed Jul 05 22:42:42 UTC 2023
DSLD 3807 (Number of products:4)
Created by admin on Wed Jul 05 22:42:42 UTC 2023 , Edited by admin on Wed Jul 05 22:42:42 UTC 2023
NCI_THESAURUS C2198
Created by admin on Wed Jul 05 22:42:42 UTC 2023 , Edited by admin on Wed Jul 05 22:42:42 UTC 2023
EU-Orphan Drug Capsaicin
Created by admin on Wed Jul 05 22:42:42 UTC 2023 , Edited by admin on Wed Jul 05 22:42:42 UTC 2023
WHO-VATC QN01BX04
Created by admin on Wed Jul 05 22:42:42 UTC 2023 , Edited by admin on Wed Jul 05 22:42:42 UTC 2023
FDA ORPHAN DRUG 205705
Created by admin on Wed Jul 05 22:42:42 UTC 2023 , Edited by admin on Wed Jul 05 22:42:42 UTC 2023
Code System Code Type Description
IUPHAR
2486
Created by admin on Wed Jul 05 22:42:42 UTC 2023 , Edited by admin on Wed Jul 05 22:42:42 UTC 2023
PRIMARY
RS_ITEM_NUM
1091108
Created by admin on Wed Jul 05 22:42:42 UTC 2023 , Edited by admin on Wed Jul 05 22:42:42 UTC 2023
PRIMARY
HSDB
954
Created by admin on Wed Jul 05 22:42:42 UTC 2023 , Edited by admin on Wed Jul 05 22:42:42 UTC 2023
PRIMARY
DRUG CENTRAL
3064
Created by admin on Wed Jul 05 22:42:42 UTC 2023 , Edited by admin on Wed Jul 05 22:42:42 UTC 2023
PRIMARY
RXCUI
1992
Created by admin on Wed Jul 05 22:42:42 UTC 2023 , Edited by admin on Wed Jul 05 22:42:42 UTC 2023
PRIMARY RxNorm
EVMPD
SUB13229MIG
Created by admin on Wed Jul 05 22:42:42 UTC 2023 , Edited by admin on Wed Jul 05 22:42:42 UTC 2023
PRIMARY
CHEBI
3374
Created by admin on Wed Jul 05 22:42:42 UTC 2023 , Edited by admin on Wed Jul 05 22:42:42 UTC 2023
PRIMARY
FDA UNII
S07O44R1ZM
Created by admin on Wed Jul 05 22:42:42 UTC 2023 , Edited by admin on Wed Jul 05 22:42:42 UTC 2023
PRIMARY
ECHA (EC/EINECS)
206-969-8
Created by admin on Wed Jul 05 22:42:42 UTC 2023 , Edited by admin on Wed Jul 05 22:42:42 UTC 2023
PRIMARY
SMS_ID
100000076831
Created by admin on Wed Jul 05 22:42:42 UTC 2023 , Edited by admin on Wed Jul 05 22:42:42 UTC 2023
PRIMARY
WIKIPEDIA
CAPSAICIN
Created by admin on Wed Jul 05 22:42:42 UTC 2023 , Edited by admin on Wed Jul 05 22:42:42 UTC 2023
PRIMARY
CAS
404-86-4
Created by admin on Wed Jul 05 22:42:42 UTC 2023 , Edited by admin on Wed Jul 05 22:42:42 UTC 2023
PRIMARY
MERCK INDEX
M3040
Created by admin on Wed Jul 05 22:42:42 UTC 2023 , Edited by admin on Wed Jul 05 22:42:42 UTC 2023
PRIMARY Merck Index
MESH
D002211
Created by admin on Wed Jul 05 22:42:42 UTC 2023 , Edited by admin on Wed Jul 05 22:42:42 UTC 2023
PRIMARY
INN
10145
Created by admin on Wed Jul 05 22:42:42 UTC 2023 , Edited by admin on Wed Jul 05 22:42:42 UTC 2023
PRIMARY
PUBCHEM
1548943
Created by admin on Wed Jul 05 22:42:42 UTC 2023 , Edited by admin on Wed Jul 05 22:42:42 UTC 2023
PRIMARY
DAILYMED
S07O44R1ZM
Created by admin on Wed Jul 05 22:42:42 UTC 2023 , Edited by admin on Wed Jul 05 22:42:42 UTC 2023
PRIMARY
NSC
56353
Created by admin on Wed Jul 05 22:42:42 UTC 2023 , Edited by admin on Wed Jul 05 22:42:42 UTC 2023
PRIMARY
EPA CompTox
DTXSID9020241
Created by admin on Wed Jul 05 22:42:42 UTC 2023 , Edited by admin on Wed Jul 05 22:42:42 UTC 2023
PRIMARY
DRUG BANK
DB06774
Created by admin on Wed Jul 05 22:42:42 UTC 2023 , Edited by admin on Wed Jul 05 22:42:42 UTC 2023
PRIMARY
ChEMBL
CHEMBL294199
Created by admin on Wed Jul 05 22:42:42 UTC 2023 , Edited by admin on Wed Jul 05 22:42:42 UTC 2023
PRIMARY
NCI_THESAURUS
C339
Created by admin on Wed Jul 05 22:42:42 UTC 2023 , Edited by admin on Wed Jul 05 22:42:42 UTC 2023
PRIMARY
Related Record Type Details
HABANERO
PARENT -> CONSTITUENT ALWAYS PRESENT
48.6% of Capsaicinoid components.
LOCOTO
PARENT -> CONSTITUENT ALWAYS PRESENT
48.6% of Capsaicinoid components.
PAPRIKA
PARENT -> CONSTITUENT ALWAYS PRESENT
48.6% of Capsaicinoid components.
CAPSICUM
PARENT -> CONSTITUENT ALWAYS PRESENT
48.6% of Capsaicinoid components.
Structure of DAVASAICIN
DERIVATIVE -> PARENT
CYTOCHROME P450 2C9
METABOLIC ENZYME -> SUBSTRATE
Structure of CAPSAICIN
EXCRETED UNCHANGED
There is no human excretion information available for capsaicin
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
WEAK
TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL SUBFAMILY V MEMBER 1
TARGET -> AGONIST
ROCOTO
PARENT -> CONSTITUENT ALWAYS PRESENT
48.6% of Capsaicinoid components.
CYTOCHROME P450 2D6
METABOLIC ENZYME -> SUBSTRATE
WEAK
CYTOCHROME P450 2C19
METABOLIC ENZYME -> SUBSTRATE
CYTOCHROME P450 2E1
METABOLIC ENZYME -> SUBSTRATE
WEAK
Related Record Type Details
Structure of (6E)-8-HYDROXY-N-((4-HYDROXY-3-METHOXYPHENYL)METHYL)-8-METHYL-6-NONENAMIDE
METABOLITE -> PARENT
MAJOR
PLASMA
Structure of VOCACAPSAICIN
PRODRUG -> METABOLITE ACTIVE
HYDROLYSIS INDEPENDENT OF ENZYME
Structure of VANILLIC ACID
METABOLITE -> PARENT
In incubation medium and skin vanillic acid ranged from 0.11 to 7.97% of the radioactivity in each sample at all concentrations.
SKIN
Structure of Vanillin
METABOLITE -> PARENT
MINOR
PLASMA
Structure of VANILLYLAMINE
METABOLITE -> PARENT
In incubation medium and skin vanillylamine ranged from 4.37 to 19.8% of the radioactivity in each sample at all concentrations.
SKIN
Structure of (6E)-N-((4-HYDROXY-3-METHOXYPHENYL)METHYL)-8-METHYL-6,8-NONADIENAMIDE
METABOLITE -> PARENT
In human microsomal fraction, 16,17-dehydro-capsaicin was the minor metabolite, but in human S-9 fraction, 16,17-dehydro-capsaicin was the major metabolite.
PLASMA
Structure of (6E)-9-HYDROXY-N-((4-HYDROXY-3-METHOXYPHENYL)METHYL)-8-METHYL-6-NONENAMIDE
METABOLITE -> PARENT
MAJOR
PLASMA
Related Record Type Details
Structure of CAPSAICIN
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966